Published in Am J Ophthalmol on March 01, 2002
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 2.40
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04
Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol (2007) 1.64
Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol (2008) 1.45
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol (2009) 1.41
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest (2008) 1.39
Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol (2013) 1.30
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
Lasting controversy on ranibizumab and bevacizumab. Theranostics (2011) 1.15
Effects of diabetes on the eye. Invest Ophthalmol Vis Sci (2013) 1.10
Involvement of Müller glial cells in epiretinal membrane formation. Graefes Arch Clin Exp Ophthalmol (2009) 1.05
Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema. Biomed Opt Express (2015) 1.04
Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. Mediators Inflamm (2012) 1.02
Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One (2012) 1.00
The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol (2012) 1.00
Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol (2009) 0.99
The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol (2010) 0.98
Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop. Mol Vis (2010) 0.97
Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Invest Ophthalmol Vis Sci (2009) 0.97
Induction of ischemic tolerance protects the retina from diabetic retinopathy. Am J Pathol (2011) 0.95
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol (2011) 0.92
The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res (2012) 0.91
Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol (2014) 0.89
Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes (2013) 0.89
Current status of anti-vascular endothelial growth factor therapy in Europe. Jpn J Ophthalmol (2008) 0.85
Generation of transgenic mice with mild and severe retinal neovascularisation. Br J Ophthalmol (2005) 0.85
Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol (2007) 0.84
The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway. Drug Des Devel Ther (2015) 0.83
Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy. Med Hypothesis Discov Innov Ophthalmol (2013) 0.83
FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression. Invest Ophthalmol Vis Sci (2014) 0.82
Intravitreal bevacizumab treatment for refractory diabetic macular edema. Int Ophthalmol (2013) 0.80
Early Avastin management in acute retinal vein occlusion. Saudi J Ophthalmol (2010) 0.79
Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. Clin Ophthalmol (2007) 0.79
A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage. Br J Ophthalmol (2007) 0.78
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture. Transl Vis Sci Technol (2016) 0.78
Environmental enrichment protects the retina from early diabetic damage in adult rats. PLoS One (2014) 0.78
Effects of intravitreal bevacizumab (Avastin) on the porcine retina. Graefes Arch Clin Exp Ophthalmol (2011) 0.77
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema. Clin Ophthalmol (2015) 0.77
Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review. J Ophthalmic Vis Res (2015) 0.77
Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF. Int J Mol Sci (2014) 0.77
Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review. J Ophthalmic Vis Res (2012) 0.76
Stem cell therapies in the treatment of diabetic retinopathy and keratopathy. Exp Biol Med (Maywood) (2015) 0.76
Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy. J Ophthalmic Vis Res (2016) 0.75
Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion. Int J Ophthalmol (2016) 0.75
The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes (2015) 0.75
Towards a rational approach to combination therapy for neovascular age-related macular degeneration. Br J Ophthalmol (2007) 0.75
Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis. Eye (Lond) (2015) 0.75
The effect of intravitreal vascular endothelial growth factor on inner retinal oxygen delivery and metabolism in rats. Exp Eye Res (2015) 0.75
The role of aflibercept in the management of diabetic macular edema. Drug Des Devel Ther (2015) 0.75
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmol Ther (2017) 0.75
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J (2004) 5.33
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology (2005) 3.20
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J (2002) 2.90
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol (2003) 2.58
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006) 2.52
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 2.40
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med (2003) 2.39
Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood (2005) 2.37
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
Developmental basis of nanophthalmos: MFRP Is required for both prenatal ocular growth and postnatal emmetropization. Ophthalmic Genet (2008) 2.15
VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci (2003) 2.09
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol (2005) 1.97
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res (2005) 1.84
Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci (2002) 1.71
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J (2002) 1.63
Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci (2004) 1.56
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 1.39
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci (2007) 1.38
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci (2011) 1.33
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci (2007) 1.32
The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci (2003) 1.28
Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci (2004) 1.27
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci (2003) 1.22
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci (2006) 1.22
The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas. Exp Eye Res (2005) 1.21
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 1.21
Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.18
betaA3/A1-crystallin in astroglial cells regulates retinal vascular remodeling during development. Mol Cell Neurosci (2007) 1.18
VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci (2003) 1.17
Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci (2002) 1.15
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology (2007) 1.12
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci (2002) 1.11
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration. Br J Ophthalmol (2011) 1.09
Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci (2003) 1.07
Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid. Exp Eye Res (2003) 1.06
Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas. Diabetes (2005) 1.06
Vascular precursors in developing human retina. Invest Ophthalmol Vis Sci (2008) 1.05
Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea (2003) 1.05
A rat model for choroidal neovascularization using subretinal lipid hydroperoxide injection. Am J Pathol (2010) 1.05
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol (2009) 1.04
The embryonic human choriocapillaris develops by hemo-vasculogenesis. Dev Dyn (2007) 1.04
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol (2007) 1.03
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci (2003) 1.03
Low nitric oxide synthases (NOSs) in eyes with age-related macular degeneration (AMD). Exp Eye Res (2009) 1.03
Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am (2006) 1.02
Retinal and optic nerve head pathology in Susac's syndrome. Ophthalmology (2011) 1.02
Lama1 mutations lead to vitreoretinal blood vessel formation, persistence of fetal vasculature, and epiretinal membrane formation in mice. BMC Dev Biol (2011) 1.02
Mutation in the βA3/A1-crystallin gene impairs phagosome degradation in the retinal pigmented epithelium of the rat. J Cell Sci (2011) 1.01
VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One (2013) 1.01
Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration. Arch Ophthalmol (2008) 0.99
Maturation of the fetal human choriocapillaris. Invest Ophthalmol Vis Sci (2009) 0.98
Retinal vascular development and oxygen-induced retinopathy: a role for adenosine. Prog Retin Eye Res (2003) 0.98
Role of Nrf2 in retinal vascular development and the vaso-obliterative phase of oxygen-induced retinopathy. Exp Eye Res (2010) 0.97
Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res (2002) 0.97
Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol (2003) 0.96
Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization. Invest Ophthalmol Vis Sci (2009) 0.96
Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am (2002) 0.95
Canine retinal angioblasts are multipotent. Exp Eye Res (2006) 0.94
The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci (2002) 0.93
Hyperoxia inhibits several critical aspects of vascular development. Dev Dyn (2007) 0.93
Mechanisms for sickle red blood cell retention in choroid. Curr Eye Res (2002) 0.93
Targeting the Effect of VEGF in Diabetic Macular Edema. N Engl J Med (2015) 0.93